First research of use Vero-Fludarabine in chronic lymphocytic leukemia and non-hodgkins lymphoma
The aim of the investigation was to estimate Vero-Fludarabine in chronic lymphocytic leukemia and non-Hodgkin’s lymphoma patients. We report the activity of three combinations of Vero-Fludarabine, one with cyclophosphamide (Vero-FluCy), the second with cyclophosphamide plus rubida (Vero-FLUCYr) and...
Saved in:
| Main Authors: | , |
|---|---|
| Format: | Article |
| Language: | Russian |
| Published: |
ABV-press
2022-11-01
|
| Series: | Онкогематология |
| Subjects: | |
| Online Access: | https://oncohematology.abvpress.ru/ongm/article/view/678 |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
| _version_ | 1850024510983503872 |
|---|---|
| author | S. S. Bessmeltsev K. M. Abdulkadyrov |
| author_facet | S. S. Bessmeltsev K. M. Abdulkadyrov |
| author_sort | S. S. Bessmeltsev |
| collection | DOAJ |
| description | The aim of the investigation was to estimate Vero-Fludarabine in chronic lymphocytic leukemia and non-Hodgkin’s lymphoma patients. We report the activity of three combinations of Vero-Fludarabine, one with cyclophosphamide (Vero-FluCy), the second with cyclophosphamide plus rubida (Vero-FLUCYr) and 3rd with rituximab (VeroFCR). For patients with chronic lymphocytic leukemia who received Vero-FluCy the overall response rate was 66.6%. Of the 9 patients, who received Vero-FluCy, 33.3% achieved complete remission and 33.3% partial remission. For patients with follicular lymphoma grades 1 and 2 who received Vero-FLUCYr or VeroFCR the overall response rate was 100%. The treatment was well tolerated. Hematologic toxicity included neutropenia and thrombocytopenia. 24% patients who received Vero-FluCy were complicated by infections. Nonhematologic toxicity was mild.We conclude that Vero-Fludarabine is an effective treatment in previously untreated or in pretreated patients with chronic lymphocytic leukemia and follicular lymphomas. |
| format | Article |
| id | doaj-art-39b34bd8208c4ebdadaab5e49b0816d9 |
| institution | DOAJ |
| issn | 1818-8346 2413-4023 |
| language | Russian |
| publishDate | 2022-11-01 |
| publisher | ABV-press |
| record_format | Article |
| series | Онкогематология |
| spelling | doaj-art-39b34bd8208c4ebdadaab5e49b0816d92025-08-20T03:01:06ZrusABV-pressОнкогематология1818-83462413-40232022-11-0104737810.17650/1818-8346-2007-0-4-73-78556First research of use Vero-Fludarabine in chronic lymphocytic leukemia and non-hodgkins lymphomaS. S. Bessmeltsev0K. M. Abdulkadyrov1Russian Research Institute of Hematology and TransfusiologyRussian Research Institute of Hematology and TransfusiologyThe aim of the investigation was to estimate Vero-Fludarabine in chronic lymphocytic leukemia and non-Hodgkin’s lymphoma patients. We report the activity of three combinations of Vero-Fludarabine, one with cyclophosphamide (Vero-FluCy), the second with cyclophosphamide plus rubida (Vero-FLUCYr) and 3rd with rituximab (VeroFCR). For patients with chronic lymphocytic leukemia who received Vero-FluCy the overall response rate was 66.6%. Of the 9 patients, who received Vero-FluCy, 33.3% achieved complete remission and 33.3% partial remission. For patients with follicular lymphoma grades 1 and 2 who received Vero-FLUCYr or VeroFCR the overall response rate was 100%. The treatment was well tolerated. Hematologic toxicity included neutropenia and thrombocytopenia. 24% patients who received Vero-FluCy were complicated by infections. Nonhematologic toxicity was mild.We conclude that Vero-Fludarabine is an effective treatment in previously untreated or in pretreated patients with chronic lymphocytic leukemia and follicular lymphomas.https://oncohematology.abvpress.ru/ongm/article/view/678vero-fludarabinenon-hodgkin’s lymphomachronic lymphocytic leukemia |
| spellingShingle | S. S. Bessmeltsev K. M. Abdulkadyrov First research of use Vero-Fludarabine in chronic lymphocytic leukemia and non-hodgkins lymphoma Онкогематология vero-fludarabine non-hodgkin’s lymphoma chronic lymphocytic leukemia |
| title | First research of use Vero-Fludarabine in chronic lymphocytic leukemia and non-hodgkins lymphoma |
| title_full | First research of use Vero-Fludarabine in chronic lymphocytic leukemia and non-hodgkins lymphoma |
| title_fullStr | First research of use Vero-Fludarabine in chronic lymphocytic leukemia and non-hodgkins lymphoma |
| title_full_unstemmed | First research of use Vero-Fludarabine in chronic lymphocytic leukemia and non-hodgkins lymphoma |
| title_short | First research of use Vero-Fludarabine in chronic lymphocytic leukemia and non-hodgkins lymphoma |
| title_sort | first research of use vero fludarabine in chronic lymphocytic leukemia and non hodgkins lymphoma |
| topic | vero-fludarabine non-hodgkin’s lymphoma chronic lymphocytic leukemia |
| url | https://oncohematology.abvpress.ru/ongm/article/view/678 |
| work_keys_str_mv | AT ssbessmeltsev firstresearchofuseverofludarabineinchroniclymphocyticleukemiaandnonhodgkinslymphoma AT kmabdulkadyrov firstresearchofuseverofludarabineinchroniclymphocyticleukemiaandnonhodgkinslymphoma |